BACKGROUND: Approved on-demand treatments for hereditary angioedema attacks need to be administered parenterally, a route of administration that is associated with delays in treatment or withholding of therapy. METHODS: In this phase 3, double-blind, three-way crossover trial, we randomly assigned participants at least 12 years of age with type 1 or type 2 hereditary angioedema to take up to two oral doses of sebetralstat (300 mg or 600 mg) or placebo for an angioedema attack. The primary end point, assessed in a time-to-event analysis, was the beginning of symptom relief, defined as a rating of "a little better" on the Patient Global Impression of Change scale (ratings range from "much worse" to "much better") at two or more consecutive time points within 12 hours after the first administration of the trial agent. Key secondary end points, assessed in a time-to-event analysis, were a reduction in attack severity (an improved rating on the Patient Global Impression of Severity [PGI-S] scale, with ratings ranging from "none" to "very severe") at two or more consecutive time points within 12 hours and complete attack resolution (a rating of "none" on the PGI-S scale) within 24 hours. RESULTS: A total of 136 participants were assigned to one of six trial sequences, with 110 treating 264 attacks. The time to the beginning of symptom relief with the 300-mg dose and the 600-mg dose was faster than with placebo (P<0.001 and P = 0.001 for the two comparisons, respectively), with median times of 1.61 hours (interquartile range, 0.78 to 7.04), 1.79 hours (1.02 to 3.79), and 6.72 hours (1.34 to >12), respectively. The time to reduction in the attack severity with the 300-mg dose and the 600-mg dose was faster than with placebo (P = 0.004 and P = 0.003), with median times of 9.27 hours (interquartile range, 1.53 to >12), 7.75 hours (2.19 to >12), and more than 12 hours (6.23 to >12). The time to complete resolution was faster with the 300-mg and 600-mg doses than with placebo (P = 0.002 and P<0.001). The percentage of attacks with complete resolution within 24 hours was 42.5% with the 300-mg dose, 49.5% with the 600-mg dose, and 27.4% with placebo. Sebetralstat and placebo had similar safety profiles; no serious adverse events related to the trial agents were reported. CONCLUSIONS: Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo. (Funded by KalVista Pharmaceuticals; KONFIDENT ClinicalTrials.gov number, NCT05259917; EudraCT number, 2021-001226-21.).
Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.
randomized blinded comparisons with multiplicity control and consistent reported sensitivity analyses
The time to reduction in the attack severity with the 300-mg dose [of sebetralstat] and the 600-mg dose [of sebetralstat] was faster than with placebo (P = 0.004 and P = 0.003).
prespecified key secondary comparisons supported by the multiplicity-controlled testing hierarchy
The percentage of attacks with complete resolution within 24 hours was 42.5% with the 300-mg dose [of sebetralstat], 49.5% with the 600-mg dose [of sebetralstat], and 27.4% with placebo.
reported attack-resolution percentages consistent with the randomized time-to-event findings
Sebetralstat and placebo had similar safety profiles; no serious adverse events related to the trial agents were reported.
systematic short-term safety collection with insufficient exposure to characterize uncommon or long-term harms
In this phase 3 trial, sebetralstat, an oral plasma kallikrein inhibitor, enabled early treatment of attacks.
observed dosing times without a route comparator cannot establish that oral administration caused earlier treatment
Derived from the full evaluation — not a separate score.
Strengths
Both doses improved the prespecified attack outcomes versus placebo, extending earlier phase 2 evidence toward a practical oral on-demand option.
↳ Introduction; Results, Efficacy End Points; Figure 2
Randomized treatment sequences, double-dummy masking, and a closed-testing hierarchy support the efficacy comparisons. Intention-to-treat and rescue-related sensitivity analyses are reported as consistent with the primary results.
↳ Methods, Randomization and Statistical Analysis; Results, Efficacy End Points
The Discussion engages guidelines and historical trials rather than presenting the findings in isolation. It explicitly states that the small laryngeal subset cannot establish efficacy for those attacks.
↳ Discussion, historical-trial comparison and laryngeal-attack assessment
Limitations
Conventional treatment was used within 12 hours for 25.0% of placebo attacks versus 8.6% of 600-mg attacks. Censoring and missing-at-random assumptions therefore matter, although sensitivity analyses are reported as consistent.
↳ Methods, Statistical Analysis; Results, Attack Characteristics and Efficacy End Points
The observed median treatment time of 41 minutes does not establish that oral administration caused earlier dosing. Comparisons with observational icatibant cohorts cannot substitute for a direct route comparison.
↳ Discussion, treatment-timing comparison and final paragraph
The trial's finite exposure cannot characterize uncommon or long-term harms. Only eight laryngeal attacks occurred, additional data were missing, and severe laryngeal attacks were excluded.
↳ Methods, Interventions and Assessments; Results, Efficacy End Points and Safety Outcomes; Table 3
The double-dummy crossover trial provides consistent placebo-controlled evidence for faster symptom relief, severity reduction, and attack resolution with both sebetralstat doses. Prespecified multiplicity control and reported sensitivity analyses support the efficacy comparisons, while differential rescue use and missing-data assumptions prevent treating the analysis as assumption-free. The Discussion usefully distinguishes the trial from historical injectable-treatment studies, but its final early-treatment assertion is stronger than the uncontrolled timing evidence permits. Observed safety findings are descriptive, and the small laryngeal subset does not establish efficacy for that clinically important setting.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Strong4.2
Confidence mediumThe trial advances oral on-demand treatment from phase 2 evidence to multinational phase 3 confirmation of symptom relief, severity reduction, and resolution versus placebo. The contribution remains distinct from establishing comparative effectiveness against existing active therapies.
The blinded crossover design, prespecified multiplicity-controlled hierarchy, systematic harms collection, and reported sensitivity analyses support the randomized efficacy comparison. Differential rescue use, missing-at-random assumptions, incomplete concealment reporting, and sparse later assessments retain methodological uncertainty.
The endpoint definitions and randomized efficacy results are presented in a followable structure. The final assertion that sebetralstat enabled early treatment implies a route-related benefit that the observed treatment timing cannot identify.
"enabled early treatment of attacks"
The Discussion engages guidelines, prior phase 2 evidence, historical on-demand trials, and the principal limits of laryngeal inference. Its observational treatment-timing comparison and limited discussion of rescue-censoring assumptions leave relevant interpretive qualifications underdeveloped.
No concerns4 of 4 checks
The reported numbers and statistics are consistent with the stated results.
Ethics approval, written consent, trial registration, sponsor involvement, and sponsor-funded writing support are declared. The existence of disclosure forms and a data-sharing statement is reported, but their contents were not supplied.
Conflict of interest: declared · Ethics approval: declared · Preregistration: declared
37 of 37 checkable references verified
37 references in manuscript
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
Participant self-administration during attacks places the evidence near the intended clinical-use setting. Long-term safety, severe laryngeal efficacy, regulatory assessment, and real-world comparative performance remain steps before routine deployment.
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Riedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine
Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate
SupportedCohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine
NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.
TentativeAygören-Pürsün, Zanichelli, Cohn, et al. · 2023 · Clinical medicine
Time to use of conventional treatment within 12 h of study drug administration was significantly longer with sebetralstat versus placebo
Supported